期刊文献+

高压氧治疗对缺血性脑卒中患者血小板膜糖蛋白表达的影响 被引量:5

Effects of hyperbaric oxygen therapy on platelet membrane glycoprotein in patients with ischemic stroke
在线阅读 下载PDF
导出
摘要 目的 探讨高压氧治疗对缺血性脑卒中患者血小板膜糖蛋白表达的影响。 方法 128 例缺血性脑卒中患者随机分为67 例高压氧 +药物治疗组和 61 例单纯药物治疗组,并设对照组(健康志愿者)30 例。高压氧+药物治疗组除常规药物治疗外还每日行高压氧治疗 次 分别于入院第 日 第 1 。 1 、 10 日应用流式细胞术测定患者血小板膜糖蛋白CD31、 CD61、 CD62p、 CD63 和 PAC蛳1 的表达。 结果 高压氧+药物治疗组第 1 日和单纯药物治疗组第 1 日的血小板膜糖蛋白 CD31、 CD61、 CD62p、 CD63 和 PAC蛳1 表达均显著高于对照组(P < 0.05 或 P < 0.01)。高压氧+药物治疗组第10 日的 CD62p、 PAC蛳1 的表达均显著低于同期单纯药物治疗组(P 均 < 0.05)。 结论 高压氧治疗可以显著抑制缺血性脑卒中患者的血小板膜糖蛋白 CD62p 和 PAC蛳1 表达,影响血小板活化反应。 Objective To investigate the effects of hyperbaric oxygen therapy on platelet membrane glycoprotein in patients with ischemic stroke. Methods 128 patients with ischemic stroke were randomly divided into hyperbaric oxygen plus drug therapy group(HBO group,67 cases) and drug therapy group(61 cases). There were 30 healthy volunteers in control group. HBO group received one hyperbaric oxygen treatment a day apart from drug therapy. Using flow cytometry, we measured respectively the expression of CD31,CD61,CD62p,CD63 and PAC-1 on platelet membrane in patients with ischemic stroke on the 1st,10th day after admission. Results The expression of CD31,CD61,CD62p,CD63 and PAC-1 on platelet membrane on the 1st day in patients of HBO group or drug therapy group was significantly higher than that of control group(P < 0.05 or P < 0.01). The expression of CD62p and PAC-1 on platelet membrane on the 10th day in patients of HBO group was significantly lower than that of simultaneous drug therapy group(respectively P < 0.05,P < 0.05). Conclusions Hyperbaric oxygen therapy can effectively inhibit the expression of CD62p and PAC-1 on platelet membrane in patients with ischemic stroke, relieve platelet activation, and may improve therapeutic effect.
出处 《北京医学》 CAS 2005年第1期7-10,共4页 Beijing Medical Journal
基金 北京市自然科学基金资助项目(编号 7022013)
关键词 高压氧治疗 缺血性脑卒中 血小板膜糖蛋白 表达 Hyperbaric oxygen Ischemic stroke Platelet membrane glycoprotein
  • 相关文献

参考文献7

  • 1Quinton TM, Ozdener F, Dangelmaier J, et al. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood, 2002, 99:3228 - 3234.
  • 2Mahooti S, Graesser D, Patil S, et al.PECAM-1(CD31) expression modulates bleeding time in vivo. Am J Pathol, 2000, 157:75 - 81.
  • 3Verstraete M. Synthetic Inhibitors of Platelet glycoprotein Ⅱb/ Ⅲain clinical development. Circulation, 2000, 101:76 - 80.
  • 4Jacoby RC, Owings JT, Holmes J, et al. Platelet activation and function after trauma. J Trauma, 2001, 51:639 - 647.
  • 5Marquardt L, Ruf A, Mansmann U, et al. Course of platelet activation markers after ischemic stroke. Stroke, 2002, 33:2570 - 2574.
  • 6Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. Arteriosclerosis Thrombosis and Vascular Biology, 1999, 19:153- 158.
  • 7Ersoz G, Ocakcioglu B, Bastug M, et al. Platelet aggregation and release function in hyperbaric oxygenation. Undersea Hyperb Med.1998, 25:229 - 232.

同被引文献29

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部